Caveat regarding CMS Merit-based Incentive Payment Systems incidental adrenal nodule measure
Current Medicare MIP measures encourage radiologists not to recommend follow-up for ≤ 1 cm adrenal nodules. However, a radiologist may be the first to discover a small, subclinical pheochromocytoma. As such, recognition of the enhancement pattern of pheochromocytoma is important to ensure detection and properly guide management, which begins with clinical and laboratory assessment for elevated catecholamines.
KeywordsMerit-based Incentive Payment Systems (MIPS) Incidental adrenal nodule Pheochromocytoma Computed tomography (CT)
Compliance with ethical standards
Conflict of interest
Joseph Holman and Roberto Salvatori have nothing to disclosures. Elliot K. Fishman received grant funding from GE Healthcare and Siemens and Founder and stockholder of HipGraphics. Pamela T. Johnson is a Consultant to Oliver Wyman.
- 1.Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions– National Quality Strategy Domain: Effective Clinical Care https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_405_Claims.pdf. Accessed 5 Aug 5 2018
- 10.Sawka AM, Jaeschke R, Singh RJ, Young WF Jr (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 88:553–558CrossRefPubMedPubMedCentralGoogle Scholar